Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy
Lung cancer is the most common cause of cancer-related deaths worldwide. More efficient treatments are desperately needed. For decades, the success of platinum-based anticancer drugs has promoted the exploration of metal-based agents. Four ruthenium-based complexes have also entered clinical trials...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1035217/full |
| _version_ | 1811237401280905216 |
|---|---|
| author | Cheng Zhang Tong Kang Xinyi Wang Jiaqi Song Jia Zhang Guanying Li |
| author_facet | Cheng Zhang Tong Kang Xinyi Wang Jiaqi Song Jia Zhang Guanying Li |
| author_sort | Cheng Zhang |
| collection | DOAJ |
| description | Lung cancer is the most common cause of cancer-related deaths worldwide. More efficient treatments are desperately needed. For decades, the success of platinum-based anticancer drugs has promoted the exploration of metal-based agents. Four ruthenium-based complexes have also entered clinical trials as candidates of anticancer metallodrugs. However, systemic toxicity, severe side effects and drug-resistance impeded their applications and efficacy. Stimuli-responsiveness of Pt- and Ru-based complexes provide a great chance to weaken the side effects and strengthen the clinical efficacy in drug design. This review provides an overview on the stimuli-responsive Pt- and Ru-based metallic anticancer drugs for lung cancer. They are categorized as endo-stimuli-responsive, exo-stimuli-responsive, and dual-stimuli-responsive prodrugs based on the nature of stimuli. We describe various representative examples of structure, response mechanism, and potential medical applications in lung cancer. In the end, we discuss the future opportunities and challenges in this field. |
| first_indexed | 2024-04-12T12:23:46Z |
| format | Article |
| id | doaj.art-e6695fc669ca46dd8efa23d8f99392bd |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T12:23:46Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-e6695fc669ca46dd8efa23d8f99392bd2022-12-22T03:33:13ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.10352171035217Stimuli-responsive platinum and ruthenium complexes for lung cancer therapyCheng Zhang0Tong Kang1Xinyi Wang2Jiaqi Song3Jia Zhang4Guanying Li5The Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, ChinaDepartment of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, ChinaThe Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, ChinaDepartment of Biophysics, School of Basic Medical Sciences, Xi’an Jiaotong University, Xi’an, Shaanxi, ChinaThe Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, ChinaDepartment of Biophysics, School of Basic Medical Sciences, Xi’an Jiaotong University, Xi’an, Shaanxi, ChinaLung cancer is the most common cause of cancer-related deaths worldwide. More efficient treatments are desperately needed. For decades, the success of platinum-based anticancer drugs has promoted the exploration of metal-based agents. Four ruthenium-based complexes have also entered clinical trials as candidates of anticancer metallodrugs. However, systemic toxicity, severe side effects and drug-resistance impeded their applications and efficacy. Stimuli-responsiveness of Pt- and Ru-based complexes provide a great chance to weaken the side effects and strengthen the clinical efficacy in drug design. This review provides an overview on the stimuli-responsive Pt- and Ru-based metallic anticancer drugs for lung cancer. They are categorized as endo-stimuli-responsive, exo-stimuli-responsive, and dual-stimuli-responsive prodrugs based on the nature of stimuli. We describe various representative examples of structure, response mechanism, and potential medical applications in lung cancer. In the end, we discuss the future opportunities and challenges in this field.https://www.frontiersin.org/articles/10.3389/fphar.2022.1035217/fullstimuli-responsivemetallic prodrugslung cancerPt anticancer drugsRu anticancer drugs |
| spellingShingle | Cheng Zhang Tong Kang Xinyi Wang Jiaqi Song Jia Zhang Guanying Li Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy Frontiers in Pharmacology stimuli-responsive metallic prodrugs lung cancer Pt anticancer drugs Ru anticancer drugs |
| title | Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy |
| title_full | Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy |
| title_fullStr | Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy |
| title_full_unstemmed | Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy |
| title_short | Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy |
| title_sort | stimuli responsive platinum and ruthenium complexes for lung cancer therapy |
| topic | stimuli-responsive metallic prodrugs lung cancer Pt anticancer drugs Ru anticancer drugs |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.1035217/full |
| work_keys_str_mv | AT chengzhang stimuliresponsiveplatinumandrutheniumcomplexesforlungcancertherapy AT tongkang stimuliresponsiveplatinumandrutheniumcomplexesforlungcancertherapy AT xinyiwang stimuliresponsiveplatinumandrutheniumcomplexesforlungcancertherapy AT jiaqisong stimuliresponsiveplatinumandrutheniumcomplexesforlungcancertherapy AT jiazhang stimuliresponsiveplatinumandrutheniumcomplexesforlungcancertherapy AT guanyingli stimuliresponsiveplatinumandrutheniumcomplexesforlungcancertherapy |